Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 6

Year

2023 1

2021 1

2020 2

2019 1

2014 1

Keywords

FLT3 inhibitors 1

AMLTargeted therapy 1

Antibiotic resistance 1

CCB 1

Culturomics 1

Gilteritinib 1

Golgi apparatus 1

Metagenomics 1

Methylene blue 1

Midostaurin 1

NIR imaging 1

NIR-AZA 1

NIR-II fluorescence 1

NIR-fluorophores 1

Quizartinib 1

Real-time imaging 1

Renal function 1

Resistome 1

Sorafenib 1

Urinary system 1

open ︾

Search scope:

排序： Display mode:

Synthesis and properties of water-soluble 1,9-dialkyl-substituted BF

Dan Wu, Gonzalo Durán-Sampedro, Donal F. O’Shea

Frontiers of Chemical Science and Engineering 2020, Volume 14, Issue 1, Pages 97-104 doi: 10.1007/s11705-019-1828-x

Abstract: Both fluorophores exhibited excellent near-infrared (NIR) photophysical properties in methanol and aqueousTheir simple synthesis, with potential for last-step structural modifications, makes the present NIR-activeazadipyrromethene derivatives potentially useful as NIR fluorescence imaging probes for live cells.

Keywords： NIR-fluorophores live cell imaging NIR-AZA

HTML PDF Collect

Water-soluble BODIPY and aza-BODIPY dyes: synthetic progress and applications

Gang FAN,Le YANG,Zhijian CHEN

Frontiers of Chemical Science and Engineering 2014, Volume 8, Issue 4, Pages 405-417 doi: 10.1007/s11705-014-1445-7

Abstract: In recent years, boron-dipyrromethene (BODIPY) and boron-azadipyrromethene (aza-BODIPY) dyes have attractedrecent progress on the synthesis, optical properties and application of water-soluble BODIPY dyes and aza-BODIPY

Keywords： boron-dipyrromethene boron-azadipyrromethene synthetic progress applications

HTML PDF Collect

Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia Review

Rowe, Nir Weigert

Engineering 2021, Volume 7, Issue 10, Pages 1354-1368 doi: 10.1016/j.eng.2021.05.020

Abstract:

Modern therapy of acute myeloid leukemia (AML) began in 1973 with the first report of the successful combination of daunorubicin and cytarabine, which led to complete remission in approximately 45% of patients. Accurate AML diagnosis was dependent on morphology, aided initially only by cytochemistry. Unlike acute lymphoblastic leukemia (ALL), immunophenotyping offered little in the diagnosis of AML, at least during the 1970s and 1980s. The advent of reliable cytogenetics changed the entire prognostic outlook of AML. With karyotypic analysis, different groups of AML could be classified and stratified for various therapies. Unique mutational profiling was a major advance in further categorizing AML patients, aided by the immunophenotypic identification of antigenic markers on the cells. All these advances were occurring as the understanding of the importance of the tumor burden—known as minimal residual disease (MRD)—became crucial for the management of AML patients. The efficacy of MRD has rapidly progressed in the past decade, from a specificity of 10⁻³ with immunophenotyping to 10⁻⁴ with polymerase chain reaction (PCR), which is only appropriate for some patients with AML, and finally to 10⁻⁵ or even 10⁻⁶ cells with the extraordinary sensitivity of next-generation sequencing (NGS). All of these advances have promoted the concept of personalized medicine, which has led to the advent of targeted agents that can accurately be used for specific diagnostic subtypes. Responses can be predicted and measured accurately. Such targeted agents have now become a cornerstone in the management of AML, increasing efficacy and dramatically reducing toxicity. The focus of this review is on one of the most well-studied targeted agents in AML: the FMS-like tyrosine kinase 3 (FLT3) inhibitors, which have impacted the prognostication and therapeutics of AML. This review selectively discusses the FLT3 inhibitors in detail, as a model for the other burgeoning targeted agents that have already been approved, as well as those that are currently in development.

Keywords： AMLTargeted therapy FLT3 inhibitors Midostaurin Gilteritinib Quizartinib Sorafenib

HTML PDF Collect

Culturomics and metagenomics: In understanding of environmental resistome

Monika Nowrotek, Łukasz Jałowiecki, Monika Harnisz, Grażyna Anna Płaza

Frontiers of Environmental Science & Engineering 2019, Volume 13, Issue 3, doi: 10.1007/s11783-019-1121-8

Abstract:

State of the art of culturomics and metagenomics to study resistome was presented.

The combination of culturomics and metagenomics approaches was proposed.

The research directions of antibiotic resistance study has been suggested.

Keywords： Culturomics Metagenomics Antibiotic resistance Resistome

HTML PDF Collect

Near-infrared fluorescent probe for fast track of cyclooxygenase-2 in Golgi apparatus in cancer cells

Bhaskar Gurram, Miao Li, Jiangli Fan, Jingyun Wang, Xiaojun Peng

Frontiers of Chemical Science and Engineering 2020, Volume 14, Issue 1, Pages 41-52 doi: 10.1007/s11705-019-1796-1

Abstract: Cyclooxygenase-2 (COX-2) has been used as an excellent traceable biomarker, and exists maximally in Golgi apparatus (Cancer cells). Celecoxib (CCB) is a selective inhibitor for COX-2, and has been used as one of non-steroidal anti-inflammatory drug. Herein we report the conjugation of nile blue (NB) with CCB via a six-carbon linkage to form a fluorescence probe NB-C6-CCB for the detection of COX-2. NB-C6-CCB displays strong fluorescence with the emission peak centered at near-infrared wavelength (700 nm) in tumor cells or tumor tissues with high expression of COX-2. Importantly, NB-C6-CCB can discriminate cancer cells (MCF-7) fluorescence intensity from normal ones (COS-7) in the co-culture medium under confocal microscope. Subcellular localization of the NB-C6-CCB preferentially points to the Golgi apparatus and increases the fluorescent intensity. The competitive analysis (with CCB) and Native-PAGE analysis confirmed that NB-C6-CCB shows selective binding affinity towards COX-2 enzyme. Competitive analysis with CCB (flow cytometry assay) revealed the fluorescence intensity fluctuation due to pretreatment of CCB with different concentrations, indicating that the NB-C6-CCB is a precise or sensitive probe for the COX-2. Tumor tissue (depth: 500 µm), organs and mice imaging tests show excellent near-infrared visualization, specific localization and identification of tumors.

Keywords： cyclooxygenase-2 nile blue CCB Golgi apparatus NIR imaging

HTML PDF Collect

Structural and Functional NIR-II Fluorescence Bioimaging in Urinary System via Clinically Approved Dye Article

Dingwei Xue,Di Wu,Zeyi Lu,Jochen Neuhaus,Abudureheman Zebibula,Zhe Feng,Sheng Cheng,Jing Zhou,Jun Qian,Gonghui Li

Engineering 2023, Volume 22, Issue 3, Pages 149-158 doi: 10.1016/j.eng.2021.07.032

Abstract: Fluorescence bioimaging in the second near-infrared spectral region (NIR-II, 1000–1700 nm)Herein, we first report in vivo NIR-II fluorescence imaging of the urinary system enabled by a clinicallyThese results demonstrate that MB assisted NIR-II fluorescence imaging holds a great promise for structural

Keywords： NIR-II fluorescence Methylene blue Renal function Urinary system Real-time imaging